Keywords: Merck & Co, BGI, China, Collaboration, Biomarkers, Genomic technology

Merck & Co and China’s BGI confirm strategic collaboration on biomarkers and genomic technologies

Article | 15 September 2011

Print This

Under a previously-signed statement of intent, US drugs giant Merck & Co (NYSE: MRK), and China-based BGI (formerly the Beijing ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in